 |
30 years of GCP quality clinical trials |
|
Large number of experienced trial sites |
|
Clinical Research spending approx US$0.25bn (2002) |
|
English-speaking country |
|
Clinical practices and training most resemble UK/USA |
|
Population > 47 million |
|
Inverse seasons (year-round enrolment) |
|
Stringent ICH-compliant health regulatory and ethical
review policies
(approximately 3-month CT approval time) |
|
Frequently among highest-recruiting countries in multi-national
studies |
|
Competitive pricing |
|
Mix of first and third world disease patterns |
| |
|
Causes of death |
| |
|
6% perinatal; 5% TB; 4% diarrhoea; 7.5%
injury; 5% respiratory infection;
29.8% HIV |
|
7% geriatric; 8% stroke; 5% ischaemic heart
disease; |
|
|
|
Approximately 0.7 medical practitioners/1 000 population |
|
Research in both public and private sectors |
|
Ideal gateway to sites in neighbouring countries |
|
Extensive multi-disciplinary network of experienced
investigators |
|
High standards of clinical practice and rapid enrolment
potential |
|
Among 10 highest contributing clinical trial countries
in the world |
|
Stringent ICH-compliant health regulatory and ethical
review policies |
|
High rate of successful audit by multinational companies
and FDA |
|
English is first language |
|
Cost attractive relative to developed countries |
|
Year 2000 spending on clinical research = US$120 million
(excludes monitor infrastructure costs) |
|
Industry and CRO trial infrastructure employs 2 367
trained persons
(estimate from Wits Health Consortium survey of pharmaceutical
research, July 2000) |
